Imfinzi met a primary endpoint of statistically-significant and clinically-meaningful progression-free survival (PFS) in ‘all-comer’ patients with locally-advanced, unresectable (Stage III) non-small cell lung cancer in a planned interim analysis
Tralokinumab did not meet its primary endpoint of a significant reduction in the annual asthma exacerbation rate
Second pivotal Phase III trial STRATOS 2 is ongoing with results expected in second half of 2017
AstraZenecaand MedImmune, its global biologics research and development arm, today announced that tralokinumab, an anti-interleukin-13 (IL-13) human monoclonal antibody, did not meet i
Idag tilldelas Överläkare Mikael Johansson, verksam vid Cancercentrum, Norrlands Universitetssjukhus, SLUSG-stipendiet 2017. Stipendiet har instiftats av Svenska Lungcancerstudiegruppen (SLUSG) och AstraZeneca och uppmärksammar personer som bidrar med betydande insatser inom lungcancerområdet.
En positiv start med fortsatt nyhetsflöde kring vår forskningsportfölj i det som har potential att bli ett avgörande år för bolaget
Full approval follows Tagrisso’s expedited Conditional Marketing Authorisation as first-in-class medicine for patients with locally-advanced or metastatic EGFR T790M mutation-positive non-small cell lung cancer
Conversion from accelerated to full approval confirms the potential of Tagrissoto become standard of care in the US Approval based on Phase III AURA3 trial thatdemonstrated significant improvement in progression-free survival with Tagrisso as compared to chemotherapy
AstraZeneca and its global biologics research and development arm, MedImmune, today announced that the European Medicines Agency (EMA) has granted orphan designation to inebilizumab (formerly MEDI-551) for the treatment of neuromyelitis optica spectrum disorder (NMOSD).
60 abstracts from early oncology portfolio including 7 oral presentations, across Tumour Drivers and Resistance, Immuno-Oncology, Antibody-Drug Conjugates and DNA Damage Response Potential new medicines targeting cancer cell-death mechanisms highlight potential of emerging Tumour Drivers and Resistance research
First AstraZeneca medicine approved under China’s new Priority Review pathway Tagrisso is an important new medicine in a country where lung cancer is the leading cause of cancer-related deaths and EGFR-mutation rates are among highest globally
Banbrytande data från en internationell observationsstudie av över 300 000 patienter med typ-2 diabetes visar att behandling med SGLT-2-hämmare minskade risken för sjukhusinläggning på grund av hjärtsvikt med 39% och den totala mortaliteten med 51%.
Circassia will lead promotion of Tudorza and prepare for potential launch of Duaklir in the US Strategic collaboration further sharpens AstraZeneca’s respiratory focus on Symbicort, Bevespi Aerosphere, benralizumab and other development programmes
AstraZeneca today announced that the US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for ZS-9 (sodium zirconium cyclosilicate).
Lynparza minskade risken för sjukdomsprogression med 70 %, med en prövarbedömd progressionsfri överlevnad på 19,1 månader, jämfört med 5,5 månader för placebo En blindad, oberoende central granskning visade en progressionsfri överlevnad på 30,2 månader, jämfört med 5,5 månader för placebo
MedImmune, the global biologics research and development arm of AstraZeneca, and Sanofi Pasteur, the vaccines division of Sanofi, today announced an agreement to develop and commercialise MEDI8897 jointly.
Qtern fixed-dose combination will provide an additional oral medicine option for patients taking Farxiga (dapagliflozin) to improve blood sugar level
AstraZeneca to receive upfront payment and sustainable and ongoingsales-based income Agreement expands the commercial potential of Zoladex in US and Canada
Updated Study 1108 data presented at ASCO GU demonstrate compelling clinical activity in patients that had previously progressed during or after one line of standard platinum-based chemotherapy
Lynparza provided a statistically-significant improvement in progression-free survival compared to chemotherapy First positive randomised trial to evaluate the efficacy and safety of a PARP inhibitor beyond ovarian cancer
Approval triggers $130 million milestone payment to AstraZeneca from US Partner Valeant Pharmaceuticals
Stiftelsen för strategisk forskning (SSF) satsar minst 75 miljoner kronor i ett AstraZeneca-samarbete om att paketera biologiska läkemedel i nanokapslar för att nå in i kroppens celler och bota svåra sjukdomar.